Initiation Setting and Persistence of Medications Affecting Cognition in Older Adults

Why It Matters

Persistent prescribing of cognition‑impairing drugs drives preventable adverse events in seniors, raising urgent calls for targeted deprescribing and safer prescribing practices across care settings.

Key Takeaways

• Antipsychotics and sedatives prescribed to 1 in 5 older adults.
• 68% of initiations occur in outpatient primary‑care visits.
• One‑year persistence exceeds 50% for most cognition‑affecting drugs.
• Persistent use linked to higher subsequent fall hospitalizations.
• Deprescribing interventions could cut adverse events by up to 30%.

Pulse Analysis

The aging population faces a paradox: medications designed to manage psychiatric or neurological conditions often exacerbate cognitive decline, increasing the risk of delirium, falls, and institutionalization. Antipsychotics, benzodiazepines, and certain antihistamines are among the most frequently cited culprits. As Medicare enrollment swells, the financial and human costs of medication‑related complications have become a focal point for policymakers seeking to improve senior health outcomes while containing expenditures.

The RAND analysis leveraged a nationally representative cohort from the Health and Retirement Study, merged with Medicare Part D prescription data spanning more than a decade. Researchers traced the point of first prescription—whether in hospital discharge, specialist consultation, or routine primary‑care visit—and tracked continuation rates a year later. Results revealed that nearly seven‑tenths of initiations happen during outpatient primary‑care encounters, and more than half of patients remain on these agents after twelve months, underscoring a systemic inertia in medication management for older adults.

These insights carry clear implications for health systems and regulators. Targeted deprescribing programs, especially within primary‑care practices, could dramatically reduce fall‑related hospitalizations and associated costs. Moreover, integrating cognitive risk alerts into electronic health records may prompt clinicians to reconsider high‑risk prescriptions at the point of care. As the evidence base grows, stakeholders—from Medicare administrators to senior advocacy groups—must collaborate to embed safer prescribing pathways, ensuring that treatment benefits outweigh the hidden cognitive hazards.